SEC Form 4/A · accession 0001192482-19-000063
Zynerba Pharmaceuticals, Inc. · ZYNE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Armando Anido
Officer — Chairman & Chief Exec. Officer · Director
Period of report
Jan 24, 2019
Accepted (ET)
Jan 30, 2019 · 4:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621443
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $3.65 | Jan 24, 2019 | A | 160,000 | A | — | Jan 24, 2029 | Common Stock | 160,000 | 160,000 | D |
Explanation of responses
- F1The stock option vests 25% on the first anniversary of the grant date, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company.
- F2Due to a clerical error, the reporting person is filing this Amendment to correct the expiration date of the stock options from 1/24/2019 to 1/24/2029.